University of Pennsylvania

Contact Info:

Ron Drapkin

https://www.med.upenn.edu/OCRCBioTrust/

Grants and Identifiers:

RRID: RRID:SCR_022387

Instrumentation:

Services Provided:

Relevant Publications:

1.) de Santiago PR, Sato S, Zhang SJ, Dougher MC, Devins KM, Bilecz AJ, Rayamajhi S, Mingo G, Rendulich HS, Feng Y, Wu C, Taylor MS, Zhuravlev Y, Jung E, Omran DK, Wang TL, Shih IM, Schwartz LE, Kim S, Morgan MA, Tanyi JL, Burns KH, Lengyel E, Parra-Herran C, Godwin AK, Walt DR, Drapkin R (2025 Mar 6). LINE-1 ORF1p expression occurs in clear cell ovarian carcinoma precursors and is a candidate blood biomarker. NPJ precision oncology, 9(1), 62. . PMCID: 11885553.

2.) Medina JE, Annapragada AV, Lof P, Short S, Bartolomucci AL, Mathios D, Koul S, Niknafs N, Noë M, Foda ZH, Bruhm DC, Hruban C, Vulpescu NA, Jung E, Dua R, Canzoniero JV, Cristiano S, Adleff V, Symecko H, van den Broek D, Sokoll LJ, Baylin SB, Press MF, Slamon DJ, Konecny GE, Therkildsen C, Carvalho B, Meijer GA, Andersen CL, Domchek SM, Drapkin R, Scharpf RB, Phallen J, Lok CAR, Velculescu VE (2025 Jan 13). Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers. Cancer discovery, 15(1), 105-118. . PMCID: 11726017.

3.) Xu H, Gitto SB, Ho GY, Medvedev S, Shield-Artin K, Kim H, Beard S, Kinose Y, Wang X, Barker HE, Ratnayake G, Hwang WT, Hansen RJ, Strouse B, Milutinovic S, Hassig C, Wakefield MJ, Vandenberg CJ, Scott CL, Simpkins F (2024 Jul 19). CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience, 27(7), 109978. . PMCID: 11253285.

4.) Tubridy EA, Eiva MA, Liu F, Omran DK, Gysler S, Brown EG, Roy AG, Zeng Y, Oh J, Cao Q, Gitto SB, Powell DJ Jr (2024 May). CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival. Gynecologic oncology, 184(), 74-82. . PMCID: 11179985.

5.) Hippen AA, Omran DK, Weber LM, Jung E, Drapkin R, Doherty JA, Hicks SC, Greene CS (2023 Oct 20). Performance of computational algorithms to deconvolve heterogeneous bulk ovarian tumor tissue depends on experimental factors. Genome biology, 24(1), 239. . PMCID: 10588129.

Description:

The Ovarian Cancer Research Center (OCRC) has opened a Tumor BioTrust Collection (TBC) to the Penn research community on July 1, 2018. Specimens that are available through the OCRC TBC include gynecologic cancer specimens such as fresh and frozen tissues, plasma, serum, peripheral blood mononuclear cells, blood, formalin fixed paraffin embedded (FFPE) samples, Tissue Microarrays (TMAs), and various types of samples collected from rapid autopsies. All samples collected have clinical annotation including demographic patient profiles, pathological & clinical notations, treatment history, and detail disease information, etc. We are building and maintaining a centralized research database according to HIPPA specifications and Penn IRB standards.